Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)
11.98
+0.08 (0.67%)
Feb 4, 2026, 3:00 PM CST
SHA:603439 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,735 | 2,144 | 1,634 | 1,201 | 938.84 | 630.15 |
Other Revenue | 0.55 | 0.55 | 0.51 | 0.33 | 0.13 | 0.08 |
| 1,736 | 2,144 | 1,635 | 1,201 | 938.97 | 630.22 | |
Revenue Growth (YoY) | -17.84% | 31.16% | 36.10% | 27.94% | 48.99% | -28.69% |
Cost of Revenue | 533.89 | 652.98 | 437.99 | 339.52 | 277.07 | 208.98 |
Gross Profit | 1,202 | 1,491 | 1,197 | 861.8 | 661.89 | 421.25 |
Selling, General & Admin | 972.89 | 1,089 | 879.21 | 618.01 | 492.75 | 304.23 |
Research & Development | 36.06 | 46.5 | 30.61 | 17.86 | 7.68 | 5.63 |
Other Operating Expenses | 17.13 | 17.31 | 16.6 | 11.01 | 8.56 | 5.38 |
Operating Expenses | 1,024 | 1,163 | 929.77 | 657.18 | 509.98 | 316.38 |
Operating Income | 178.1 | 328.34 | 267.22 | 204.62 | 151.92 | 104.87 |
Interest Expense | -11.82 | -14.61 | -4.13 | -5.24 | -8.34 | -2.2 |
Interest & Investment Income | 2.96 | 5.8 | 60.13 | 17.56 | 25.81 | 7.69 |
Other Non Operating Income (Expenses) | 5.79 | -0.37 | 1.89 | -0.21 | -0.09 | -0.08 |
EBT Excluding Unusual Items | 175.03 | 319.16 | 325.1 | 216.74 | 169.29 | 110.28 |
Impairment of Goodwill | - | - | - | -0.08 | - | - |
Gain (Loss) on Sale of Investments | -2.84 | 0.15 | - | -0.09 | - | - |
Gain (Loss) on Sale of Assets | 0.09 | -0.17 | 0.59 | -0.09 | -0.15 | - |
Asset Writedown | -1.02 | -0.57 | -0.05 | -0.1 | -0.01 | - |
Other Unusual Items | 13.15 | 6.47 | 8.38 | 6.18 | 7.51 | -0.38 |
Pretax Income | 184.41 | 325.03 | 334.02 | 222.56 | 176.65 | 109.9 |
Income Tax Expense | 19.68 | 45.19 | 39.15 | 30.62 | 28.05 | 15.95 |
Earnings From Continuing Operations | 164.73 | 279.84 | 294.87 | 191.94 | 148.6 | 93.95 |
Minority Interest in Earnings | -4.05 | -5.81 | -2.17 | 9.35 | 3.68 | 0 |
Net Income | 160.68 | 274.03 | 292.7 | 201.28 | 152.28 | 93.95 |
Net Income to Common | 160.68 | 274.03 | 292.7 | 201.28 | 152.28 | 93.95 |
Net Income Growth | -51.14% | -6.38% | 45.42% | 32.18% | 62.08% | -29.40% |
Shares Outstanding (Basic) | 402 | 409 | 412 | 411 | 412 | 391 |
Shares Outstanding (Diluted) | 402 | 409 | 412 | 411 | 412 | 391 |
Shares Change (YoY) | -3.85% | -0.79% | 0.36% | -0.19% | 5.14% | 5.90% |
EPS (Basic) | 0.40 | 0.67 | 0.71 | 0.49 | 0.37 | 0.24 |
EPS (Diluted) | 0.40 | 0.67 | 0.71 | 0.49 | 0.37 | 0.24 |
EPS Growth | -49.19% | -5.63% | 44.90% | 32.43% | 54.17% | -33.33% |
Free Cash Flow | 37.3 | 61.87 | 167.97 | 173.38 | 128.96 | 11.54 |
Free Cash Flow Per Share | 0.09 | 0.15 | 0.41 | 0.42 | 0.31 | 0.03 |
Dividend Per Share | 0.340 | 0.340 | 0.200 | 0.100 | - | 0.250 |
Dividend Growth | 70.00% | 70.00% | 100.00% | - | - | - |
Gross Margin | 69.24% | 69.55% | 73.21% | 71.74% | 70.49% | 66.84% |
Operating Margin | 10.26% | 15.31% | 16.34% | 17.03% | 16.18% | 16.64% |
Profit Margin | 9.26% | 12.78% | 17.90% | 16.75% | 16.22% | 14.91% |
Free Cash Flow Margin | 2.15% | 2.89% | 10.27% | 14.43% | 13.73% | 1.83% |
EBITDA | 280.21 | 402.3 | 303.64 | 220.44 | 163.09 | 112.98 |
EBITDA Margin | 16.14% | 18.76% | 18.57% | 18.35% | 17.37% | 17.93% |
D&A For EBITDA | 102.11 | 73.96 | 36.42 | 15.82 | 11.17 | 8.11 |
EBIT | 178.1 | 328.34 | 267.22 | 204.62 | 151.92 | 104.87 |
EBIT Margin | 10.26% | 15.31% | 16.34% | 17.03% | 16.18% | 16.64% |
Effective Tax Rate | 10.67% | 13.90% | 11.72% | 13.76% | 15.88% | 14.51% |
Revenue as Reported | 1,736 | 2,144 | 1,635 | 1,201 | 938.97 | 630.22 |
Advertising Expenses | - | 1.47 | 1.78 | 2.29 | 0.01 | 0 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.